Menu
Your Cart

Apostle MiniMax Technology


Overview

The ability to isolate and analyze circulating cell free DNA (cfDNA) at very low concentrations is becoming increasingly important, particularly in non-invasive prenatal test (NIPT), early cancer detection, and infectious disease diagnosis. Highly efficient isolation of cfDNA from complexed biological medium is a crucial step for subsequent cfDNA analysis. 

Apostle MiniMax® technology offers a best-in-class efficiency and purity compared with conventional technologies to capture and isolate the circulating cell-free genetic materials.

Performance Assessment

Apostle MiniMax technology offers a best-in-class efficiency and purity compared with conventional technologies to capture and isolate the circulating cell-free genetic materials. It is trusted by many of the world's most prestigious leaders in life sciences.

Independently Published Performance Assessment Data


(Figure 4) - "Most notably, the Apostle particles outperformed all others, achieving almost 2-fold higher recovery yields than the particles supplied in the X kit. "


Figure 1. cfDNA extraction method affects allele frequency (AF%). EGFR L858R standards with AF% of 0.3%, 1.0%, and 3.0% were spiked into plasma and isolated using Product A (red) or Apostle MiniMax cfDNA isolation kit (blue and green). The eluates were analyzed by NGS (performed by the Institute B) following standard protocol and AF% calculated using their established workflow. cfDNA isolated by Apostle MiniMax cfDNA isolation kit shows higher concordance between detected AF% and expected AF%

This link directs to an external page, reviewing the performance and data of Apostle MiniMax by Beckman Coulter Life Sciences. 2019

(Figure 1) "For each tube the Apostle MiniMax extracted higher total yield of DNA. "


This link directs to an external Application Note. This application note compares workflows and yield for the extraction of cfDNA using Apostle MiniMax High Efficiency cfDNA Isolation Kit, following the manual protocol, automating the extraction using the Biomek i7 Hybrid Workstation, and semi-automating the extraction using the KingFisher Duo Prime Sample Purification System.

This link directs to an external Application Note. This application note compares workflows and yield for the extraction of cfDNA using Apostle MiniMax High Efficiency cfDNA Isolation Kit, following the manual protocol, automating the extraction using the Biomek i7 Hybrid Workstation, and semi-automating the extraction using the KingFisher Duo Prime Sample Purification System.

This link directs to an external poster presented at ASHG 2019. This poster presents the data associated with correlation between mutations found In FFPE tumor tissue and paired cfDNA samples.

This link directs to an external poster presented at ASHG 2019. This poster presents the data associated with the comparison between mutation profiles of paired whole blood and cfDNA samples.

This link directs to an external poster presented at AACR 2019. This poster presents a comparison of matched FFPE and plasma samples to determine how many mutations are seen in both tissues.

This link directs to an external poster presented at AGBT 2019. This poster presents a novel cfDNA extraction kit and show its compatibility with extractions from 200 µl – 5 mL.


For a complete list of publications, visit here.

Applications

Apostle MiniMax technology has been applied in world-class research and development projects of novel liquid biopsy technologies.  

For a more detailed discussion, visit hereSome examples include:

Apostle MiniMax Technology in Clinical Research on Metastatic Solid Tumors

Apostle MiniMax Technology in Hepatocellular Carcinoma Detection

Apostle MiniMax Technology in HIV Research & Clinical Trial

Apostle MiniMax Technology in Colon Cancer Detection and Post-Surgical Monitoring

Apostle MiniMax Technology in Detecting Chromosomal Structural Abnormalities in Patients with Myeloid Neoplasms

Apostle MiniMax Technology in Rectal Cancer Response Prediction and Risk Stratification

Apostle MiniMax Technology in Non-Invasive Prenatal Testing

Apostle MiniMax Technology in Prenatal Diagnostics using ddPCR

Apostle MiniMax Technology in Early Gender Prediction

Apostle MiniMax Technology in Cardiovascular Research

Apostle MiniMax Technology in Next Generation Digital PCR

Significance

A recent paper published in JAMA Oncology by Torga & Pienta revealed that, strikingly, 2 major commercial liquid biopsy tests show significant and clinically unacceptable discordance. 

Why do liquid biopsy tests differ so significantly? Are they reliable? 

Among other impact factors, the extraction method of circulating free DNA (cfDNA) plays a major role here. Data show that different cfDNA extraction methods yield significantly different amounts of cfDNA by 10% to 10 folds, and consequently result in discordant conclusions. When we study genomic DNA isolated from the nucleus of cells, this level of difference may not matter much – because the amount of genetic material commonly reaches hundreds of micrograms (ug), so the downstream testing methods have enough genetic material to work with anyway. However, when we study cfDNA, this level of difference may result in a fundamental discordance, because the amount of cfDNA is commonly less than 100 nanograms (ng). Slight difference of cfDNA yields may result in critical impact on the testable copies of cancer mutations and the signal-to-noise ratio. 

We illustrate how the accuracy of a liquid biopsy is impacted by the cfDNA sample preparation in a figure below. To have a reliable liquid biopsy testing, a highly efficient cfDNA extraction must be achieved.

Exhibit 1. Sample preparation is a critical yet unaddressed challenge in liquid biopsy.

Uniqueness

Apostle MiniMax technology ensures precise capture and separation of circulating genetic materials for liquid biopsy analysis. This is achieved through Apostle’s novel proprietary MiniMax magnetic nanoparticles (Exhibit 2-8) with innovative features:

  • Novel material composition and surface chemistry - completely distinct from the conventional paramagnetic or superparamagnetic technologies
  • Exceptionally large surface area
  • Minimized variation
  • Best-in-class suspension property
  • Superb magnetic power
  • Superb resistance to particle clustering
  •  Superior cfDNA isolation efficiency
  • Superior performance of DNA mutation detection 

Exhibit 2. Apostle’s proprietary MiniMax magnetic nanoparticles under scanning electron microscope.

The Apostle MiniMax nanoparticles have an increased magnetic strength and a decreased particle size compared to other leading technologies in the market, which ensures excellent suspension in solution and rapid mobility. The optimized surface chemistry allows efficient enrichment of genetic materials from complex biological materials.

Exhibit 3. Apostle’s proprietary MiniMax nanoparticles have uniform sizes.

Apostle’s MiniMax magnetic nanoparticles generated from our proprietary technology have a uniform size distribution with minimized doublets, distinct from the particles from five current technological providers showing random sizes and significant doublets. Highly consistent size distribution of Apostle’s nanoparticles ensure reproducible results.

Exhibit 4. The Apostle MiniMax nanoparticles have a best-in-class suspension property.

Excellent suspension is one of the critical properties of nanoparticles to excel in cfDNA isolation. In this simple but quite visual experiment, we compare Apostle MiniMax with the nanoparticles from other two technologies on the market. The three tubes contain equal weight of different types of nanoparticles. By 1 minute, the other technology #2 is almost completely sedimented. By 15 minute, the other technology #1 is almost completely sedimented. However, Apostle MiniMax has kept the suspension status, showing a superb suspension property.  


https://www.youtube.com/watch?v=ym63t4oLnkQ

Exhibit 5. The Apostle MiniMax nanoparticles have a best-in-class magnetic power.

A strong magnetic power is another critical property of nanoparticles to achieve a good cfDNA isolation performance. In this simple experiment, we compare the magnatic power of Apostle MiniMax with the nanoparticles from other two technologies on the market. The three tubes contain equal weight of different types of nanoparticles. A magnetic plate slowly approaches the three tubes at equal distances. Whichever tube having the strongest magnetic power makes the first move. 
The tube containing Apostle MiniMax makes the first move, while the other two technologies stay still. Apostle MiniMax shows a superb magnetic power.

https://www.youtube.com/watch?v=6SDVUoYzD9Y

Exhibit 7. Superior cfDNA isolation efficiency in human plasma and urine.

A) Cell-free plasma was separated from blood samples by centrifugation for 10 minutes at 2000g at 4oC, then centrifuged for 10 minutes at 16000g at 4oC. cfDNA was isolated from 4mL plasma with Apostle MiniMax High Efficiency cfDNA Isolation Kit (red curve) and major alternative product (blue curve). The isolated cfDNA was characterized by Bioanalyzer 2100. 

B) Cell-free urine was prepared by centrifugation for 10 minutes at 16000g at 4oC. cfDNA was isolated from 20mL urine with Apostle MiniMax High Efficiency cfDNA Isolation Kit (red curve) and major alternative product (blue curve). The isolated cfDNA was characterized by Bioanalyzer 2100. Apostle MiniMaxTM High Efficiency cfDNA Isolation Kit offers superior cfDNA isolation efficiency for both plasma and urine samples.

Exhibit 6. The Apostle MiniMax nanoparticles have a superb resistance to particle clustering.

The unwanted clustering of particles reduces the performance of the cfDNA isolation, and sometimes even interferes with the normal lab procedures. In this experiment, we compare MiniMax's ability to resist clustering with another leading technology on the market. After adding isopropyl alcohol, the other technology shows particle clustering visible to naked eye, while Apostle MiniMax does not. The Apostle MiniMax nanoparticles show a superb resistance to particle clustering. 

Large Image

Exhibit 8. Superior performance of DNA mutation detection isolated with Apostle MiniMax High Efficiency Cell-Free DNA Isolation Kit

20 uL of DNA fragment containing the EGFR c.2573T>G L858R mutation (synthetic, ~170 bp), with concentration of 1 ng/uL, 0.1 ng/uL, 0.01 ng/uL, 0.001 ng/uL, was spiked into 1mL TE buffer (blue) or Serum (red) respectively. The mutated DNA fragment was isolated with Apostle MiniMax High Efficiency Cell-Free DNA Isolation Kit (Standard Edition), with a final elution volume of 20 uL. qPCR was performed using 1 uL of the isolated DNA, and compared with 1 uL of the corresponding original mutated DNA solution at 1 ng/uL, 0.1 ng/uL, 0.01 ng/uL, 0.001 ng/uL. 

A) Amplification plot showing highly overlapping curves for mutated DNA fragment isolated with Apostle MiniMaxTM High Efficiency Cell-Free DNA Isolation Kit and original DNA solution at different concentrations. 

B) qPCR standard curve generated using original mutated DNA solution, in order to quantify the recovery of DNA isolated with Apostle MiniMax High Efficiency Cell-Free DNA Isolation Kit. DNA isolation recovery rate was calculated to be >90%. 

Note: Displayed DNA concentration series at 1, 0.1, 0.01, 0.001 ng/ul are the concentrations of the original DNA dilution series before spiking into 1mL of serum. The corresponding DNA isolation working concentrations are 20 pg/ul, 2 pg/ul, 0.2 pg/ul, 0.02 pg/ul, respectively.

Other Information

Apostle also partners with Beckman Coulter to offer the Apostle MiniMaxTM High Efficiency Isolation Kit. If you wish to order the kit through Beckman Coulter, please visit Beckman Coulter's website:

Apostle image 
https://www.beckman.com/reagents/genomic/dna-isolation/from-plasma

For more information about this partnership: https://www.beckman.com/news/liquid-biopsy-partnership-with-apostle

ProductsCat#
Apostle MiniMaxTM High Efficiency Cell-Free DNA Isolation Kit (Standard Edition) (1mL X 10 preps)A17622-10
Apostle MiniMaxTM High Efficiency Cell-Free DNA Isolation Kit (Standard Edition) (1mL X 50 preps)A17622-50
Apostle MiniMaxTM High Efficiency Cell-Free DNA Isolation Kit (Standard Edition) (5mL X 50 preps)A17622-250
For research use only. Not for use in diagnostic procedures.
Using Apostle MiniMax cfDNA Isolation Technology a recent clinical study in 2821 myeloid or lymphoid neoplasm patients shows that liquid biopsy using targeted NGS is reliable in detecting chromosomal structural abnomalities in myeloid neoplasms. The study supports the use of liquid biopsy for early diagnosis and monitoring of patients with myeloid neoplasms. Read article